NL0 Stock Overview
A biotechnology company, focuses on developing technologies for early cancer detection.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GRAIL, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.30 |
| 52 Week High | US$19.60 |
| 52 Week Low | US$11.20 |
| Beta | 0 |
| 11 Month Change | 6.96% |
| 3 Month Change | -14.88% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| NL0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.2% | -0.4% | -1.8% |
| 1Y | n/a | -14.9% | 13.2% |
Return vs Industry: Insufficient data to determine how NL0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how NL0 performed against the German Market.
Price Volatility
| NL0 volatility | |
|---|---|
| NL0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine NL0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,360 | Bob Ragusa | grail.com |
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests.
GRAIL, Inc. Fundamentals Summary
| NL0 fundamental statistics | |
|---|---|
| Market cap | €388.24m |
| Earnings (TTM) | -€2.66b |
| Revenue (TTM) | €101.27m |
3.8x
P/S Ratio-0.1x
P/E RatioIs NL0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NL0 income statement (TTM) | |
|---|---|
| Revenue | US$109.74m |
| Cost of Revenue | US$195.28m |
| Gross Profit | -US$85.54m |
| Other Expenses | US$2.80b |
| Earnings | -US$2.88b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | -92.86 |
| Gross Margin | -77.95% |
| Net Profit Margin | -2,627.35% |
| Debt/Equity Ratio | 0% |
How did NL0 perform over the long term?
See historical performance and comparison